Boston, MA, May 14, 2014 --(PR.com
)-- Panel Discussion on “Value Maximization vs. Capital Efficiency” features executives from AbbVie, Celgene, Johnson & Johnson, and Sofinnova Ventures at the 3rd Oncology Partnering & Deal-Making Conference (July 7-8, 2014, in Boston, MA).
Panel participants include John Gustofson, Senior Director of Ventures & Early Stage Collaborations at AbbVie; Winston Kung, Chief Business Officer at Celgene; Nick D’Aleandro, Senior Director of Business Development at Johnson & Johnson; Jay Shepard, Executive Partner at Sofinnova Ventures.
GTCBio's 3rd Oncology Partnering & Deal-Making Conference is a partnership and business development conference that provides an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the industry. Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, partnership opportunities, alliance management, value maximization vs. capital efficiency, and the rebirth of IPOs. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum.
This conference is part of the larger Novel Cancer Therapeutics Summit, which consists of two co-located parallel conferences:
3rd Oncology Partnering & Deal-Making Conference
5th Cancer Targets & Therapeutics Conference
For more information, please visit www.gtcbio.com